<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="letter" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">ESMO Open</journal-id><journal-id journal-id-type="iso-abbrev">ESMO Open</journal-id><journal-id journal-id-type="pmc-domain-id">3084</journal-id><journal-id journal-id-type="pmc-domain">esmo</journal-id><journal-title-group><journal-title>ESMO Open</journal-title></journal-title-group><issn pub-type="epub">2059-7029</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12476095</article-id><article-id pub-id-type="pmcid-ver">PMC12476095.1</article-id><article-id pub-id-type="pmcaid">12476095</article-id><article-id pub-id-type="pmcaiid">12476095</article-id><article-id pub-id-type="pmid">40961643</article-id><article-id pub-id-type="doi">10.1016/j.esmoop.2025.105812</article-id><article-id pub-id-type="pii">S2059-7029(25)01681-3</article-id><article-id pub-id-type="publisher-id">105812</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Correspondence</subject></subj-group></article-categories><title-group><article-title>Letter to the editor re: CDX2 expression as a predictive and prognostic biomarker of 5-fluorouracil response in cancer of unknown primary</article-title></title-group><contrib-group><contrib contrib-type="author" id="au1"><name name-style="western"><surname>Kr&#228;mer</surname><given-names initials="A">A.</given-names></name><email>a.kraemer@dkfz.de</email><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref></contrib><aff id="aff1"><label>1</label>Clinical Cooperation Unit Molecular Hematology/Oncology, German Cancer Research Center (DKFZ) and University of Heidelberg, Heidelberg, Germany</aff><aff id="aff2"><label>2</label>Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany</aff></contrib-group><pub-date pub-type="collection"><month>10</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>16</day><month>9</month><year>2025</year></pub-date><volume>10</volume><issue>10</issue><issue-id pub-id-type="pmc-issue-id">497711</issue-id><elocation-id>105812</elocation-id><pub-history><event event-type="pmc-release"><date><day>16</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>28</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-28 18:25:14.327"><day>28</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 The Author(s)</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="main.pdf"/><related-article xmlns:xlink="http://www.w3.org/1999/xlink" related-article-type="article-reference" xml:lang="en" xlink:title="research-article" journal-id="ESMO Open" journal-id-type="nlm-ta" ext-link-type="pmc" xlink:href="PMC12309936"><article-title>CDX2 expression as a predictive and prognostic biomarker of 5-FU response in cancer of unknown primary</article-title><volume>10</volume><issue>8</issue><date><day>23</day><month>7</month><year>2025</year></date><elocation-id>105515</elocation-id><source>ESMO Open</source><pub-id pub-id-type="doi">10.1016/j.esmoop.2025.105515</pub-id><pub-id pub-id-type="pmcid">PMC12309936</pub-id><pub-id pub-id-type="pmid">40706223</pub-id></related-article><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p id="p0010">I read with interest the article by Fuentes Bayne et al.,<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref> in which they report a retrospective analysis on the impact of 5-fluorouracil (5-FU) treatment in 209 patients with caudal type homeobox 2 (CDX2)-positive cancer of unknown primary (CUP). They find that 5-FU-based regimens were associated with significantly higher overall response rate, and prolonged progression-free (PFS) and overall survival compared with non-5-FU regimens in CDX2-positive CUP. As these benefits were observed across CDX2-positive tumours, regardless of whether they exhibited the classical colon-like CUP immunophenotype, the authors concluded that their study identifies CDX2, a biomarker assessable by routine immunohistochemistry, as predictive of marked benefit from 5-FU-based chemotherapy, prompting broader consideration of nongenomic, phenotype-driven biomarkers in CUP.</p><p id="p0015">Regarding genomics-driven biomarkers, the authors allude to the CUPISCO study, a large international phase II trial that tested the potential of a comprehensive genomic profiling (CGP)-informed, histology-agnostic treatment strategy to improve outcomes over standard chemotherapy in patients with newly diagnosed CUP in a randomized setting.<xref rid="bib2" ref-type="bibr"><sup>2</sup></xref> Specifically, it is stated that this trial reported a modest 1.7-month improvement in PFS [6.1 months versus 4.4 months; hazard ratio (HR) 0.72, <italic toggle="yes">P</italic> = 0.0079], with most patients (78%) receiving atezolizumab &#177; chemotherapy, suggesting that the observed benefit was likely driven by immunotherapy rather than molecularly guided therapy (MGT).</p><p id="p0020">In the CUPISCO trial, 436 patients with newly diagnosed unfavourable CUP who reached disease control after three cycles of platinum-based induction chemotherapy were randomly assigned to receive either MGT or further chemotherapy. In the MGT arm, 27% of patients had an actionable genomic alteration or signature and were stratified to receive one of eleven different MGT options; the remaining 73% received continued chemotherapy plus the anti-programmed death-ligand 1 antibody atezolizumab. Median PFS from the time of randomization, the primary endpoint of the study, was significantly improved in the MGT group overall (6.1 months versus 4.4 months in the chemotherapy group; HR 0.72, <italic toggle="yes">P</italic> = 0.0079). More importantly, when the analysis was restricted to patients with tumours harbouring an actionable genomic alteration or signature, the median PFS was 8.1 months in patients receiving MGT versus 4.7 months in those with such molecular features who received chemotherapy alone in the control arm (HR 0.65). In contrast, addition of atezolizumab to platinum-based chemotherapy in patients without an actionable genomic alteration resulted in a median PFS of only 5.5 months versus 4.4 months for those treated with chemotherapy alone (HR 0.76).</p><p id="p0025">These findings clearly show that, firstly, MGT increased PFS from 4.7 months to 8.1 months in patients with unfavourable CUP and an actionable molecular target. Secondly, this benefit was almost entirely driven by matched targeted therapies, whereas the addition of immunotherapy to chemotherapy in patients without an actionable genomic alteration did not significantly increase PFS.</p><p id="p0030">Together, while retrospective data suggest that CDX2 expression might be a suitable nongenomic marker for the prediction of 5-FU response, the prospective randomized CUPISCO trial has shown that CGP-guided MGT resulted in longer PFS than standard platinum-based chemotherapy in patients with previously untreated, unfavourable CUP.</p></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name name-style="western"><surname>Fuentes Bayne</surname><given-names>H.E.</given-names></name><name name-style="western"><surname>Suleiman</surname><given-names>R.</given-names></name><name name-style="western"><surname>Eiring</surname><given-names>R.A.</given-names></name><etal/></person-group><article-title>CDX2 expression as a predictive and prognostic biomarker of 5-FU response in cancer of unknown primary</article-title><source>ESMO Open</source><volume>10</volume><year>2025</year><object-id pub-id-type="publisher-id">105515</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.esmoop.2025.105515</pub-id><pub-id pub-id-type="pmcid">PMC12309936</pub-id><pub-id pub-id-type="pmid">40706223</pub-id></element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="journal" id="sref2"><person-group person-group-type="author"><name name-style="western"><surname>Kr&#228;mer</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bochtler</surname><given-names>T.</given-names></name><name name-style="western"><surname>Pauli</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Molecularly guided therapy versus chemotherapy after disease control in unfavourable cancer of unknown primary (CUPISCO): an open-label, randomised, phase 2 study</article-title><source>Lancet</source><volume>404</volume><year>2024</year><fpage>527</fpage><lpage>539</lpage><pub-id pub-id-type="pmid">39096924</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(24)00814-6</pub-id></element-citation></ref></ref-list><ack id="ack0010"><sec id="sec1"><title>Funding</title><p id="p0035">This work is supported by the <funding-source id="gs3">Priority Program Translational Oncology</funding-source> of the <funding-source id="gs1"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100005972</institution-id><institution>Deutsche Krebshilfe</institution></institution-wrap></funding-source> [grant number 70115167].</p></sec><sec id="sec2"><title>Disclosure</title><p id="p0040"><bold>AK</bold> has received research funding from <funding-source id="gs2">Bristol Myers Squibb</funding-source>, F. Hoffmann-La Roche and Molecular Health; has received consulting fees, travel support and/or remuneration for advisory board participation from F. Hoffmann-La Roche; and has served as study oncologist for the CUPISCO trial.</p></sec></ack></back></article></pmc-articleset>